文献速递造血干细胞移植与细胞治疗

脐血来源病毒特异性T细胞在脐血移植受者中的安全性与可行性

Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients.
PubMed 文献 · Blood Adv · 2019-01-01

该研究评估了从脐血单位20%组分中体外扩增脐血来源多病毒特异性T细胞(CB-VSTs)的可行性与安全性,靶向EBV、腺病毒和CMV。在两项临床试验中,21例患者中18例(86%)成功制备CB-VSTs。未观察到与CB-VSTs输注相关的3-4级急性GVHD,7例预防性输注患者均未发生目标病毒终末器官疾病。

要点

  • 从脐血单位20%组分体外扩增CB-VSTs在86%(18/21)患者中可行。
  • CB-VSTs输注未伴随3-4级急性GVHD,且未观察到延迟植入。
  • 7例预防性输注患者未发生CMV、EBV或腺病毒终末器官疾病。

核心结论

  • 脐血来源病毒特异性T细胞(CB-VSTs)的体外扩增是可行的,且输注未伴随3-4级急性GVHD,提示其可作为抗病毒药物治疗的可行补充。

研究设计与样本

  • 在2个独立中心开展2项临床试验,评估从脐血单位20%组分体外扩增CB-VSTs的可行性与安全性,靶向EBV、腺病毒和CMV,共纳入21例接受单份脐血移植的儿科患者。

主要发现

  • 21例患者中18例(86%)成功制备CB-VSTs,2例因细胞回收不足未达到批次放行标准,1例在分离冻存20%组分时发生无菌性破坏。
  • 接受剩余80%组分进行主要脐血移植的患者未观察到延迟植入。
  • 未观察到与CB-VSTs输注相关的3-4级急性GVHD。
  • 7例预防性接受CB-VSTs的患者均未发生CMV、EBV或腺病毒终末器官疾病。
  • 7例因病毒再激活或感染接受CB-VSTs的患者中,仅1例发生终末器官病毒病(CMV视网膜炎),发生于免疫豁免部位,且在GVHD激素治疗后出现。

临床怎么用

  • 对于接受单份脐血移植的儿科患者,可从脐血单位20%组分体外扩增CB-VSTs,且不影响剩余80%组分用于主要移植的植入。
  • CB-VSTs可用于预防或治疗EBV、腺病毒和CMV再激活/感染,且未观察到与输注相关的3-4级急性GVHD。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adoptive transfer of virus-specific T cells (VSTs) has been shown to be safe and effective in stem cell transplant recipients. However, the lack of virus-experienced T cells in donor cord blood (CB) has prevented the development of ex vivo expanded donor-derived VSTs for recipients of this stem cell source. Here we evaluated the feasibility and safety of ex vivo expansion of CB T cells from the 20% fraction of the CB unit in pediatric patients receiving a single CB transplant (CBT). In 2 clinical trials conducted at 2 separate sites, we manufactured CB-derived multivirus-specific T cells (CB-VSTs) targeting Epstein-Barr virus (EBV), adenovirus, and cytomegalovirus (CMV) for 18 (86%) of 21 patients demonstrating feasibility. Manufacturing for 2 CB-VSTs failed to meet lot release because of insufficient cell recovery, and there was 1 sterility breach during separation of the frozen 20% fraction. Delayed engraftment was not observed in patients who received the remaining 80% fraction for the primary CBT. There was no grade 3 to 4 acute graft-versus-host disease (GVHD) associated with the infusion of CB-VSTs. None of the 7 patients who received CB-VSTs as prophylaxis developed end-organ disease from CMV, EBV, or adenovirus. In 7 patients receiving CB-VSTs for viral reactivation or infection, only 1 patient developed end-organ viral disease, which was in an immune privileged site (CMV retinitis) and occurred after steroid therapy for GVHD. Finally, we demonstrated the long-term persistence of adoptively transferred CB-VSTs using T-cell receptor-Vβ clonotype tracking, suggesting that CB-VSTs are a feasible addition to antiviral pharmacotherapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Abraham AA, John TD, Keller MD, et al. Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Adv. 2019. PMID: 31292125. doi:10.1182/bloodadvances.2019000201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。